Navigation Links
Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
Date:1/22/2013

dures expected in the U.S. this year and 15 million in developed countries, with a projected annual growth rate of three to four percent. There are multiple commercial opportunities within the lens replacement market, including both standard and premium lenses. The premium market includes toric, multifocal and accommodating lenses. Refractive lens exchange is also a growing segment of the lens replacement market.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding the date of the expected market launch of OMS302, when it will read out data from is OMS824 program and begin enrolling its second OMS103HP Phase 3 trial, the growth rate of the number of intraocular lens replacement procedures performed annually and that Omeros may have capability, through its GPCR prog
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
2. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
3. Omeros is Not Aware of Any Justification for Share Price Movement
4. Omeros Corporation Reports Third Quarter 2012 Financial Results
5. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
6. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
7. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
8. Omeros to Present at Two Upcoming Conferences
9. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
10. Omeros Corporation Reports Second Quarter 2012 Financial Results
11. Omeros Announces Discovery in MASP-2 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... , Oct. 2, 2014 A new Insights ... entitled, " Adherence: why it,s so hard and what ... key research findings on medication adherence and lays out ... percent through new interventions by 2017. For the past ... focused on building the body of scientific knowledge available ...
(Date:10/2/2014)... , Oct. 2, 2014   Softworld, Inc. ... a new practice solely focused on the specific needs ... While Softworld has already been highly successful in ... their additional capabilities to support the quality, regulatory, and ... is now a combination of the current Biometric team ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4CVS Health Insights Report Tackles Complex Issue of Medication Adherence 2CVS Health Insights Report Tackles Complex Issue of Medication Adherence 3Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2
... SAN DIEGO, Jan. 7, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... its academic founder and member of the Board of ... week.  He was a thoughtful leader with an incredible ... was matched by his terrific wit and disarming good ...
... N.Y., Jan. 6, 2012  VirtualScopics, Inc., (NASDAQ: ... the pharmaceutical, biotechnology and medical device industries, announced today ... from the NASDAQ Stock Market indicating that the Company,s ... consecutive business days.  NASDAQ Marketplace Rule 5550(a)(2)requires a $1.00 ...
Cached Medicine Technology:VirtualScopics Announces Receipt of Notice from Nasdaq 2VirtualScopics Announces Receipt of Notice from Nasdaq 3
(Date:10/2/2014)... Brooklyn, PA (PRWEB) October 02, 2014 ... through social engineering announced today it will host a ... The webinar will reveal the final outcome of ... at DEF CON 22 in Las Vegas and explore ... evolving social engineering attacks. To register for the ...
(Date:10/2/2014)... is a distinguished bamboo product manufacturer and retailer. Plenty ... global customers in the past few years. Now, the ... All its online workers are professional and patient; they ... company has recently added a new assortment of ... marketing specialist has announced that all these brand new ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... literally -- may face an increased risk of dying in the ... over 3,000 older Americans, researchers found those who were unable to ... three times as likely to die in the next five years, ... anosmia -- the inability to distinguish odors -- was a bigger ...
(Date:10/1/2014)... Psychiatry researchers from the University of Adelaide have developed ... likelihood of a good outcome from treatment - from ... based on a range of factors, including clinical symptoms, ... biomarkers in the patient,s blood. , Speaking in the ... the University,s Head of Psychiatry , Professor ...
Breaking Medicine News(10 mins):Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2
... PITTSBURGH, Jan. 18 Family caregivers who had not ... nearly two weeks longer to decide to forego further ... the issues, according to researchers from the University of ... Public Health. They share their findings in a poster ...
... , AMES, Iowa -- Parents may have good reason ... have been spending playing their new video games since ... team -- including an Iowa State University psychologist -- ... and that greater amounts of gaming, lower social competence ...
... BOSTON Beth Israel Deaconess Medical Center (BIDMC) investigators Lewis ... awarded the distinction of AAAS Fellows by the American Association ... members to be recognized this year for their distinguished efforts ... AAAS Annual Meeting in February. Chief of BIDMC,s Division ...
... in particular the CAMERA study, has used MRI to study ... higher proportion of these patients exhibit lesions of the brain ... Lesions of the brain microvessels , Lesions of ... of various kinds: white-matter hyperintensities and, more rarely, silent infarcts ...
... a genetic blood test and a five-minute functional MRI ... many of whom were destined to develop cognitive decline ... John Woodard, Ph.D., associate professor of psychology in ... of Gerontology at Wayne State University, is lead author ...
... Western Reserve University School of Medicine and Athersys, Inc. ... cord injury will be published today in the January ... study, by leading researchers from the Department of Neurosciences ... presents data supporting the potential therapeutic benefit of Athersys, ...
Cached Medicine News:Health News:Pitt study: End-of-life decisions take longer if patient hasn't shared wishes with family 2Health News:New Pediatrics study identifies the risks, consequences of video game addiction 2Health News:New Pediatrics study identifies the risks, consequences of video game addiction 3Health News:Migraines and headaches present no risk to cognitive function 2Health News:Migraines and headaches present no risk to cognitive function 3Health News:Wayne State University study predicts risk of memory loss in healthy, older adults 2Health News:Case Western Reserve and Athersys show regenerative benefit of MultiStem after spinal cord injury 2Health News:Case Western Reserve and Athersys show regenerative benefit of MultiStem after spinal cord injury 3
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
Medicine Products: